Home » Stocks » AgeX Therapeutics

AgeX Therapeutics, Inc. (AGE)

Stock Price: $1.66 USD 0.08 (5.06%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 62.56M
Revenue (ttm) 1.89M
Net Income (ttm) -11.81M
Shares Out 37.69M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.66
Previous Close $1.58
Change ($) 0.08
Change (%) 5.06%
Day's Open 1.58
Day's Range 1.53 - 1.80
Day's Volume 350,362
52-Week Range 0.67 - 3.93

More Stats

Market Cap 62.56M
Enterprise Value 65.73M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 37.69M
Float 20.99M
EPS (basic) -0.32
EPS (diluted) -0.31
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.38M
Short Ratio 7.97
Short % of Float 6.58%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 33.12
PB Ratio 12.96
Revenue 1.89M
Operating Income -11.82M
Net Income -11.81M
Free Cash Flow -9.63M
Net Cash -3.17M
Net Cash / Share -0.08
Gross Margin 78.56%
Operating Margin -625.46%
Profit Margin -625.10%
FCF Margin -509.85%
ROA -98.37%
ROE -453.02%
ROIC -2,706.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth23.78%-0.57%-15.73%-
Gross Profit1.481.031.241.36
Operating Income-12.56-11.25-6.66-12.74
Net Income-12.15-7.50-6.58-15.49
Shares Outstanding37.2734.9130.6428.80
Earnings Per Share-0.33-0.21-0.21-0.54
Operating Cash Flow-10.16-8.00-6.29-8.43
Capital Expenditures-0.64-0.02--0.02
Free Cash Flow-10.80-8.02-6.29-8.45
Cash & Equivalents2.356.717.380.26
Total Debt1.96---
Net Cash / Debt0.406.717.380.26
Book Value2.227.457.28-23.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AgeX Therapeutics, Inc.
Country United States
Employees 17
CEO Michael D. West

Stock Information

Ticker Symbol AGE
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: AGE
IPO Date November 29, 2018


AgeX Therapeutics, a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.